EBT-107

A Dual-guide RNA Treatment for Hepatitis B

Excision BioTherapeutics’ EBT-107 program is intended to treat individuals with hepatitis B (HBV) by targeting HBV-infected cells in the liver.

Our Pipeline

$50 Billion Market Opportunity

~1.2 million in the U.S.

~350 million patients worldwide¹

^{1) CDC, https://www.cdc.gov/hepatitis/hbv/pdfs/hepbatrisk.pdf. 2021.}

The Innovative Technology That Drives Our Programs

Our cutting-edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

Research & Publications

View our library of publications for more information on the research behind our CRISPR gene-editing technology.